CRIS Current Research Information System

MACCHINI, MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.193
NA - Nord America 2.925
EU - Europa 2.423
AF - Africa 224
SA - Sud America 188
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.957
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.885
VN - Vietnam 997
CN - Cina 825
SG - Singapore 798
IT - Italia 514
GB - Regno Unito 489
SE - Svezia 288
DE - Germania 262
HK - Hong Kong 168
FR - Francia 151
IN - India 134
BR - Brasile 132
RU - Federazione Russa 121
CH - Svizzera 111
UA - Ucraina 107
IE - Irlanda 92
NL - Olanda 76
KR - Corea 60
FI - Finlandia 57
JP - Giappone 56
ZA - Sudafrica 55
CI - Costa d'Avorio 44
TG - Togo 41
NG - Nigeria 37
EE - Estonia 35
AT - Austria 31
PH - Filippine 24
TH - Thailandia 22
BG - Bulgaria 21
SC - Seychelles 21
AR - Argentina 19
BE - Belgio 18
CA - Canada 16
JO - Giordania 16
ID - Indonesia 14
MX - Messico 14
PL - Polonia 12
TR - Turchia 11
PK - Pakistan 9
EC - Ecuador 8
ES - Italia 8
IR - Iran 8
BD - Bangladesh 7
CL - Cile 7
TW - Taiwan 7
HR - Croazia 6
CO - Colombia 5
DZ - Algeria 5
EG - Egitto 5
IQ - Iraq 5
LT - Lituania 5
NI - Nicaragua 5
PT - Portogallo 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
VE - Venezuela 5
NP - Nepal 4
PY - Paraguay 4
GR - Grecia 3
JM - Giamaica 3
KE - Kenya 3
PE - Perù 3
UY - Uruguay 3
AU - Australia 2
BO - Bolivia 2
BY - Bielorussia 2
CM - Camerun 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
IL - Israele 2
KZ - Kazakistan 2
LB - Libano 2
MA - Marocco 2
MY - Malesia 2
PS - Palestinian Territory 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AO - Angola 1
BT - Bhutan 1
BW - Botswana 1
ET - Etiopia 1
KH - Cambogia 1
ME - Montenegro 1
ML - Mali 1
MM - Myanmar 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
MR - Mauritania 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
RS - Serbia 1
SN - Senegal 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
YT - Mayotte 1
Totale 8.957
Salva come PNG Salva come JPEG
Città #
Singapore 534
Southend 437
Ashburn 340
Chandler 237
Fairfield 208
Dong Ket 204
Hanoi 176
Ho Chi Minh City 175
Hong Kong 155
Santa Clara 154
San Jose 125
Princeton 118
Houston 108
Bern 105
Wilmington 101
Beijing 99
New York 99
Hefei 93
Dublin 92
Ann Arbor 91
Woodbridge 80
Seattle 71
Dallas 65
Bologna 62
Boardman 60
Lauterbourg 60
Cambridge 57
Jacksonville 57
Helsinki 53
Seoul 51
Nanjing 49
Los Angeles 48
Westminster 47
Padova 45
Abidjan 44
Tokyo 43
Lomé 41
Rome 39
Medford 35
Milan 34
Turin 34
Abeokuta 32
Berlin 30
Shenyang 29
Da Nang 26
Jinan 26
Frankfurt am Main 25
Guangzhou 24
Haiphong 24
Saint Petersburg 24
Buffalo 22
Florence 22
Redondo Beach 22
Sofia 21
Council Bluffs 20
Mülheim 20
Dearborn 19
Hebei 19
Changsha 18
Tianjin 18
Amman 16
Nanchang 15
Shanghai 15
Vienna 14
Brussels 13
Fremont 13
Kyiv 13
Munich 13
Redwood City 13
Hangzhou 12
Nuremberg 12
Ravenna 12
San Diego 12
Taiyuan 12
Des Moines 11
Falls Church 11
Jiaxing 11
Orem 11
São Paulo 11
Bến Tre 10
Hải Dương 10
Xi'an 10
Bangkok 9
Bengaluru 9
San Venanzo 9
Warsaw 9
Yubileyny 9
Zhengzhou 9
Can Tho 8
Johannesburg 8
Kunming 8
Amsterdam 7
Atlanta 7
Brooklyn 7
Chicago 7
Falkenstein 7
Haikou 7
Jakarta 7
Nha Trang 7
Olalla 7
Totale 5.578
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 451
Characterization of pancreatic ductal adenocarcinoma using whole transcriptome sequencing and copy number analysis by single-nucleotide polymorphism array 267
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 248
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 245
Characterization of pancreatic ductal adenocarcinoma patients using whole-transcriptome sequencing and copy number analysis by SNPs array techniques. 235
β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer 235
Comparing recist and Choi’s criteria to evaluate radiological response to chemotherapy in patients with advanced pancreatic cancer 223
Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer:A literature review and report of two cases 215
Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience. 205
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 197
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 190
GemOx and Ovarian Pancreatic Cancer Metastasis (PC) 183
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: An interim report of a prospective randomized study 182
Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses 182
Clinical impact of nonselective beta-blockers on survival in patients with pancreatic cancer- revival of well known drugs? 181
State of the art biological therapies in pancreatic cancer 177
Comparing RECIST and Choi's Criteria After Neoadjuvant Chemoradiotherapy in Patients with Resectable Pancreatic Cancer 175
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) 166
Advanced pancreatic cancer (APC) A monocenter experience in 53 patients: is it possible a second line treatment? 166
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action 161
Gemox in combination witherlotinib (E) in pancreatic cancer (PC). 158
Advanced pancreatic cancer (apc); a Monocenter experience in 53 patients. It is possible a second line treatment? 156
Preoperatory Gemcitabine and Oxaliplatin in a patient with ovarian metastasis from pancreatic cystadenocarcinoma 156
The follow-up issues: from the necessity to the opportunity 151
GEMOX AS FIRST-LINE CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): A MONOINSTITUTIONAL EXPERIENCE 151
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? 150
CIRCULATING METALLOPROTEINASE-3 AND TISSUE INHIBITOR OF METALLOPROTEINASE-2 IN PATIENTS WITH DUCTAL PANCREATIC NEOPLASMS 150
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 150
Role of adjuvant chemoradiotherapy (CRT) and chemotherapy alone in pancreatic cancer: experience in 25 patients. 146
Whole-transcriptome paired-end sequencing and the pancreatic cancer genetic landscape 146
Whole Transcriptome Sequencing Reveals Molecular Prognostic Markers in Pancreatic Adenocarcinoma 145
Erratum: β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer (Cancer Cell (2018) 33(1) (75–90.e7), (S153561081730510X) (10.1016/j.ccell.2017.11.007)) 145
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI) 144
Hedgehog Signaling: from the Cuirass to the Heart of Pancreatic Cancer 144
Prognostic factors for recurrence in resected pancreatic adenocarcinoma: a single center experience 143
Massively Parallel Sequencing Analysis of Genetic Alterations Carried by Pancreatic Adenocarcinoma 142
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 140
Locally Advanced Pancreatic Cancer: Is It Possible Pancreatic Resection? A Case Report 140
Results of a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma. 138
Useful of Choi’s criteria after neoadjuvant chemoradiotherapy in patients with resectable pancreatic cancer. 137
Long-Term Survival After Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. Case Report 132
Neoadjuvant Therapy for Resectable Pancreatic Adenocarcinoma: An Interim Report of a Prospective Controlled Randomized Study 132
Prognostic factors in resected pancreatic cancer:a single centre experience 130
Whole genome discovery of genetic alterations carried by pancreatic adenocarcinoma 128
Comparing RECIST and Choi’s Criteria to Evaluate Radiological Response to Chemotherapy in Patients with Advanced Pancreatic Cancer 127
Whole Transcriptome Sequencing Reveals Somatic HMGCR Mutation in a Case of Pancreatic Adenocarcinoma with Long-Term Therapy Response 126
Comparing RECIST and Choi’s Criteria to Evaluate Radiological Response to Chemotherapy in Patients with Resectable and Advanced Pancreatic Cancer. 120
New WHO classification for pancreatic endocrine tumours: is time to leave the previous one 116
SNP-Array High Resolution Cytogenetic Analysis of Resectable and Advanced Pancreatic Cancer 110
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: an interim report of a prospective controlled randomized study. 106
Whole genome discovery of genetic alterations in resectable and advanced pancreatic cancer. 105
Resection Margin Involvement in Pancreaticoduodenectomy. A Single Centre Experience 98
Massively Parallel Sequencing Analysis of Genetic Alterations Carried by Pancreatic Adenocarcinoma 97
Role of CA 19-9 Concentration as an Independent Prognostic Factor in Unresectable Pancreatic Ductal Adenocarcinoma (PDCA) Treated with GemOx 95
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey 86
Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey 81
1517P Isolated LUng Metastases in pancreatic AdenoCArcinoma patients in a multicenter Italian cohort: The LU.M.A.CA study 78
Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial 64
Totale 9.147
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.061
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.061
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021424 0 0 0 0 0 0 0 0 0 30 32 362
2021/2022994 80 44 30 70 89 51 13 57 38 107 240 175
2022/20231.238 105 173 69 133 80 102 13 84 169 51 135 124
2023/2024405 26 44 10 37 34 135 17 31 9 21 23 18
2024/20251.251 59 136 98 66 232 56 112 87 25 95 47 238
2025/20263.071 278 282 273 232 323 172 438 106 715 252 0 0
Totale 9.147